Advice Pool - Health and Fitness

Living with type 1 diabetes is not always easy, but things have certainly changed dramatically since the middle of the last century. That might seem like a long t

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

ime ago, until you realize that people born in the 1950s are only in their 40s and 50s today.

Type 1 diabetes was not as well understood fifty years ago and its

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

management and treatment was certainly very different to that which we see today. Indeed, if you ever find yourself getting frustrated with living with diabetes,

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

it's worth taking a moment or two to compare your situation today to that of people born in the middle of the last century.

People born in the 1950s and diagnose

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

d with type 1 diabetes were looking at a death rate of about 20% within 20 years of diagnosis, rising to a staggering 30% just 25 years after diagnosis. For peopl

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

e born in the late 1970s, and who are now in their late 20s, these figures have dropped dramatically to just 3.5% and 7% respectively.

Type 1 diabetics born in t

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

he 1950s also faced a 25% chance of developing kidney failure, which in those days could not be detected in its early stages and, once detected, it was virtually

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

impossible to control the progress of the disease. Today, fewer than 10% of diabetics develop kidney disease and modern drugs such as ACE inhibitors and ARBs can

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

slow the progression of the disease and, in some cases, prevent it from developing into kidney failure.

For 90% of people with diabetes, diabetic retinopathy wou

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

ld rear its ugly head within 25 years of their diagnosis and this accounted for 20% of all cases of blindness in people between the ages of 45 and 75. Nowadays, l

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

aser eye surgery and closely monitored follow up treatment can reduce the risk of diabetic retinopathy by as much as 90%.

Diabetic mothers faced a risk in those

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

days of seeing major birth defects in their babies at about 3 times the rate seen in the general population. Today, close monitoring and control of blood glucose

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

levels throughout a pregnancy have reduced the risk to just about the same as that seen in the population at large.

In the 1950s diabetics monitored their blood

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

glucose levels by testing their urine and this meant that their tests were always looking at their past levels, rather than their current levels. The urine test a

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

lso detected only high levels of blood glucose and did not pick up often dangerously low levels.

Finally, patients had to rely on injections of animal derived in

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

sulin to treat their condition and such things as today's variety of insulin formulations, together with pumps and insulin inhalers were still in the future.

Tod

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

ay the risks from type 1 diabetes are much lower than they have ever been and the management of the condition makes living with diabetes far easier. But, much mor

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

e exciting is the future for those with type 1 diabetes.

Research over recent years means that we now understand far more about the condition and, in particular,

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

know far more about the underlying biology of diabetes. Current clinical trials and further research will undoubtedly mean that we will continue to see advances

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

in the management of the disease and, hopefully, see a solution to the problem of reversing the autoimmune destruction of insulin producing cells before too long.

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.advicepool.org.ua/article/240427/advicepool-The-Changing-Face-Of-Type-1-Diabetes.html">The Changing Face Of Type 1 Diabetes</a>

BB link (for phorums):
[url=http://www.advicepool.org.ua/article/240427/advicepool-The-Changing-Face-Of-Type-1-Diabetes.html]The Changing Face Of Type 1 Diabetes[/url]

If you're trying to sell your book or ebook online but haven't been successful, then you could use some online marketing tips from the professionals. In this article we reveal the 7 most effective online marketing tactics.

Is it easy or hard to create your own product? I have created several this year, so I think it is easy. I fyou have never created a product you probably think it is really hard.

Refinancing your home loan can be a smart move as long as you get a low rate. Here are some simple tips that can ensure you get the lowest rate possible on your Home Refinance Loan.

Tags

Links

Advice Pool - The Changing Face Of Type 1 Diabetes

Related Articles: